Drug Trial Radar · NCT07310173
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Oct 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug AST-3424 works to treat AKR1C3 high expressing advanced hepatocellular carcinoma after failure of systemic therapy with immune checkpoint inhibitors. The main question it aims to answer is: Does AST-3424 prolong survival in patients with AKR1C3-high Expressing advanced Hepatocellular Carcinoma who have progressed after immune checkpoint inhibitors based therapies? Researchers will compare AST-3424 to regorafenib (current optional therapy for target patients) to see if AST-3424 works. Participants will: Receive AST-3424 infusion on Day 1 and Day 8 of each 21-day treatment cycle or take regorafenib once a day on Day 1 -Day 21 of each 28-day treatment cycle.
Conditions
- HCC - Hepatocellular Carcinoma
Interventions
AST-3424Drug
AST-3424 is administered via intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle
Regorafenib TabletsDrug
160 mg orally, once daily for the first 21 days of each 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 9-month overall survival rateTime frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.